Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) from a hold rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

A number of other analysts also recently commented on the company. Canaccord Genuity Group increased their price target on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. Barclays cut their price objective on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. HC Wainwright assumed coverage on Madrigal Pharmaceuticals in a research note on Wednesday, November 4th. They issued a “strong-buy” rating for the company. Finally, The Goldman Sachs Group initiated coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $704.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $706.87.

Read Our Latest Stock Analysis on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $432.79 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.94 and a debt-to-equity ratio of 0.54. Madrigal Pharmaceuticals has a 52 week low of $353.54 and a 52 week high of $615.00. The firm has a 50-day moving average price of $484.73 and a two-hundred day moving average price of $497.09.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. The firm had revenue of $431.27 million for the quarter, compared to analysts’ expectations of $404.17 million. During the same quarter last year, the firm earned ($5.08) EPS. Analysts forecast that Madrigal Pharmaceuticals will post -2.08 earnings per share for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William Sibold sold 6,362 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the completion of the transaction, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at $108,707,095.53. This represents a 3.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker bought 76,140 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, November 6th. The shares were bought at an average cost of $384.32 per share, with a total value of $29,262,124.80. Following the completion of the transaction, the director directly owned 2,040,682 shares in the company, valued at approximately $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 13,324 shares of company stock worth $7,011,982 over the last three months. 17.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Concurrent Investment Advisors LLC grew its position in Madrigal Pharmaceuticals by 2.0% during the second quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock valued at $555,000 after acquiring an additional 20 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Madrigal Pharmaceuticals by 3.5% in the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 28 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Madrigal Pharmaceuticals by 2.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock worth $839,000 after acquiring an additional 43 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals by 5.5% in the 3rd quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 44 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Madrigal Pharmaceuticals by 35.4% in the 2nd quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 45 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

About Madrigal Pharmaceuticals

(Get Free Report)

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.

Recommended Stories